Last quarter (Q3 2023), Plus Therapeutics's total revenue was $1.24M, an increase of Infinity% from the same quarter last year. In Q3, Plus Therapeutics's net income was $-3.22M. See Plus Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	$ 3.82M	$ 224.00K	-	$ 303.00K	$ 7.00M	$ 2.98M
Cost of Revenue	-	-	-	-	-	$ 1.15M
Gross Profit	$ 3.60M	$ 224.00K	-	-	-	$ 5.51M
Operating Expense	$ 18.86M	$ -19.94M	$ 12.43M	$ 9.89M	$ 10.65M	$ 11.74M
Operating Income	$ -15.03M	$ -19.71M	$ -12.43M	$ -9.58M	$ -3.66M	$ -8.76M
Net Non Operating Interest Income Expense	$ -129.00K	$ -564.00K	$ -913.00K	$ -1.06M	$ -1.80M	$ -1.88M
Other Income Expense	$ 2.00K	$ -1.00K	$ 60.00K	$ 2.40M	$ 2.17M	$ 1.76M
Pretax Income	$ -15.16M	$ -20.27M	$ -13.40M	$ -8.24M	$ -3.28M	$ -8.88M
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -15.16M	$ -20.27M	$ -13.40M	$ -8.24M	$ -11.44M	$ -15.12M
Basic EPS	$ -1.89	$ -0.77	$ -1.11	$ -1.86	$ -8.27	$ -86.98
Diluted EPS	$ -1.89	$ -0.77	$ -16.65	$ -1.86	$ -8.27	$ -86.98
Basic Average Shares	$ 74.19M	$ 26.26M	$ 805.95K	$ 4.43M	$ 1.38M	$ 173.85K
Diluted Average Shares	$ 74.19M	$ 26.26M	$ 805.95K	$ 4.43M	$ 1.38M	$ 173.85K
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 18.86M	$ -19.94M	$ 12.43M	$ 9.89M	$ 10.65M	$ 11.74M
Net Income From Continuing And Discontinued Operation	$ -15.16M	$ -20.27M	$ -13.40M	$ -8.24M	$ -10.89M	$ -12.63M
Normalized Income	$ -6.83M	-	-	$ -8.24M	$ -5.46M	$ -10.64M
Interest Expense	$ 159.00K	-	-	$ 1.11M	$ 1.85M	$ 1.92M
EBIT	$ -14.67M	$ -19.56M	$ -12.47M	$ -7.13M	$ -1.43M	$ -6.96M
EBITDA	$ -13.79M	$ -18.46M	$ -11.50M	$ -6.77M	$ -532.00K	$ -4.95M

Currency in USD

Plus Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing